- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal
Vical (Nasdaq:VICL) and the Mycoses Study Group Education and Research Consortium announced the establishment of a collaboration to advance Vical’s novel antifungal drug product candidate for the treatment of invasive aspergillosis. As quoted in the press release: “We are excited to establish this collaboration with the world’s leading mycology clinicians and thought leaders,” said Dr. …
Vical (Nasdaq:VICL) and the Mycoses Study Group Education and Research Consortium announced the establishment of a collaboration to advance Vical’s novel antifungal drug product candidate for the treatment of invasive aspergillosis.
As quoted in the press release:
“We are excited to establish this collaboration with the world’s leading mycology clinicians and thought leaders,” said Dr. Mammen “Anza” Mammen, Vical’s Senior Vice President, Clinical Development. “We believe the MSGERC will add substantial value to our VL-2397 antifungal program by serving as advisors to our Phase 2 trial and helping provide exposure for the study among their member clinicians who may be interested in taking part as investigators.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.